Developing  innovative treatments

that may enable the nervous system
to repair itself

Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury.

We create innovative treatments for nervous system damage due to injury or disease.

NervGen Pharma

NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target indication is spinal cord injury.

Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury

NervGen is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of
NVG-291 in individuals with spinal cord injury.

For information regarding recruitment, the call center phone number is +1 (855) 559-6902. 

View our NervGen: the Origin Story Video

View our Corporate Presentation

Stay Connected

Subscribe to our mailing list to stay up to date

The Latest

News Release

February 15, 2024

NervGen announced it's on track to complete enrollment in Q2 2024 and deliver the data readout in Q3 2024 of the chronic cohort in it’s Phase 1b/2a proof-of-concept, double blind, randomized placebo-controlled clinical trial for NVG-291 in individuals with spinal cord injury.  

News Release

November 9, 2023

NervGen reported its financial and operational results for the third quarter ended September 30, 2023.  

Article

July 28, 2022

Unlike existing treatments that focus on rehabilitation or reducing the risk of an additional stroke, the experimental drug targets the "stickiness" that can prevent injured brain tissue from functioning as it should